Q1 2025 Earnings Call Transcript May 1, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-2.52, expectations were $-2.92. Operator: Good day, and thank you for standing by. Welcome to ...

The plans amount to an extraordinary flex of Robert F. Kennedy Jr.’s power as health secretary to make decisions ordinarily ...

FRIDAY, April 25, 2025 (HealthDay News) -- On Tuesday, the U.S. Department of Health and Human Services announced that the ...

On a Thursday conference call with investors, Moderna CFO Jamey Mock outlined a roadmap for the mRNA specialist to lower its ...

Here are eight possible indicators of how health secretary Robert F. Kennedy Jr. may handle U.S. vaccine policy in coming ...

Former government health officials fear the Trump administration is moving to slow-walk vaccine approvals, including by ...

We recently published a list of the 11 Worst Performing Stocks in S&P 500 So Far in 2025. In this article, we will take a ...

If the FDA deems Pfizer’s and Moderna’s updated vaccines “new” products, it’s extremely unlikely the doses would be ready for ...

Welcome to the Moderna First Quarter 2025 Conference ... our next-generation COVID vaccine in mRNA-1283, our RSV vaccine for high-risk adults aged 18 to 59 mRNA-1345, and our flu plus COVID ...

COVID - 19: The Company reported $84 million in Spikevax® sales in the first quarter of 2025, which includes $29 million of U.S. sales and $55 million of international sales. As previously reported, ...

Jefferies analysts said Moderna’s first quarter was “in line,” with a miss on revenue offset by a beat on earnings per share.

Moderna is currently in the very early stages of testing a bird flu vaccine using the same mRNA technology that allowed for rapid development and rollout of COVID-19 vaccines. The funds from the ...